Tóm tắt
Background: Metabolic-Associated Fatty Liver Disease (MAFLD) is affecting approximately 24% of individuals and potentially leading to cirrhosis and hepatocellular carcinoma. This study aims to assess the prevalence of MAFLD in chronic obstructive pulmonary disease (COPD) patients and analyze their clinical characteristics.
Methods: This cross-sectional descriptive study involved 120 stable COPD patients, using FibroScan to detect fatty liver, applying the 2020 APASL criteria for MAFLD diagnosis.
Results: The prevalence of MAFLD was 53.3%, with a mean age of 68.9 ± 8.1 years, predominantly male (89.2%). Patients with MAFLD had higher weight, waist circumference, and BMI compared to those without MAFLD (p<0.05). Smoking rates were high in both groups, while alcohol consumption was notably higher in the MAFLD group (70.3% vs. 50.0%, p=0.023). They also had higher rates of mMRC ≥2 (98.4% vs. 66.1%, p<0.001), higher mean CAT scores (19.9 ± 5.1 vs. 14.1 ± 5.2, p<0.001), and experienced more exacerbations (68.7% with ≥2 per year). They were more likely to belong to the E group of COPD (89.0% vs. 21.5%, p<0.001). They also had higher rates of using reliver and controller medications containing ICS; lower FVC, FEV1, FEF 25-75%, and PEF indices (p<0.05); and a higher proportion of patients in GOLD stages 3 and 4 (p=0.002). Nearly all COPD patients who had fatty liver detected by FibroScan (98.5%) also had metabolic factors qualifying them for a MAFLD diagnosis. Blood glucose, HbA1c, insulin, and HOMA-IR levels were significantly higher in the MAFLD group (p<0.05).
Conclusion: MAFLD affects 53.3% of COPD patients. It’s associated with higher weight, waist circumference, BMI, alcohol use, and inhaled corticosteroids. COPD patients with MAFLD experience more severe respiratory symptoms, poorer lung function, and more frequent exacerbations.
| Đã xuất bản | 09-05-2025 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Tập 15 Số 2 (2025) | |
| Phân mục | Nghiên cứu | |
| DOI | 10.34071/jmp.2025.2.5 | |
| Từ khóa | Metabolic-associated fatty liver disease, MAFLD, Chronic obstructive pulmonary disease, COPD, FibroScan, Fatty liver |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2025 Tạp chí Y Dược Huế
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour J-F, Schattenberg JM et al: A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology 2020, 73(1):202-209.
Eslam M, Sarin SK, Wong VW-S, Fan J-G, Kawaguchi T, Ahn SH, Zheng M-H, Shiha G, Yilmaz Y, Gani R et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International 2020, 14(6):889-919.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018, 67(1):123-133.
The top 10 causes of death.
Viglino D, Jullian-Desayes I, Minoves M, Aron-Wisnewsky J, Leroy V, Zarski J-P, Tamisier R, Joyeux-Faure M, Pépin J-L. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. European Respiratory Journal 2017, 49(6):1601923.
Su B, Liu T, Fan H, Chen F, Ding H, Wu Z, Wang H, Hou S. Inflammatory Markers and the Risk of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. PLoS One 2016, 11(4):e0150586.
Bộ Y tế. Hướng dẫn chẩn đoán và điều trị bệnh Viêm gan vi rút B (Ban hành kèm theo Quyết định số: 3310/QĐ-BYT ngày 29 tháng 7 năm 2019 của Bộ trưởng Bộ Y tế). 2019.
Nguyễn VT. Phân tích dữ liệu với R. Nhà xuất bản Tổng Hợp thành phố Hồ Chí Minh 2014.
Song JU, Jang Y, Lim SY, Ryu S, Song WJ, Byrne CD, Sung KC. Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study. PLoS One 2019, 14(1):e0208736.
Mantovani A, Lonardo A, Vinco G, Zoppini G, Lippi G, Bonora E, Loomba R, Tilg H, Byrne CD, Fabbri L et al. Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. Diabetes Metab 2019, 45(6):536-544.
Zheng Y, Qi Y, Seery S, Yang J, Li C, Wang W, Gao J, Meng X, Shao C, Tang Y-D. Elevated HsCRP in Chronic Obstructive Pulmonary Disease: A Prospective Study of Long-Term Outcomes After Percutaneous Coronary Intervention. International Journal of Chronic Obstructive Pulmonary Disease 2022:2517-2528.